Washington: A high-dose shot of a common asthma drug, once a month, has been found to be highly effective in treating teens and adults chronically afflicted with severe, itchy rash, says a new study.Known as omalizumab, the drug was tested on 323 people at 55 medical centres for whom standard antihistamine therapy failed to quell underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria."Physicians and patients may now have a fast, safe and well-tolerated treatment option to consider before prescribing even more antihistamines, which can be highly sedating," says Sarbjit (Romi) Saini, Johns Hopkins allergist and immunologist, and study co-investigator, the The New England Journal of Medicine reports.The study, from 2009 to 2011, involved mostly women aged between 12 and 75 years. Each was randomly assigned to take one of three dosing regimens of omalizumab, or placebo, after which they were monitored through regular checkups for four months, according to a Johns Hopkins statement.
Schizophrenia leads to IQ loss: Study
`Starving a fever` really works